NCT07834710
Using Bioimpedance Analysis to Monitor Fluid Status in Children
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Start date changed from estimate of Nov 2026 to Nov 5, 2026
- Notable Recruitment opened
- Start date pushed from Oct 2026 to Nov 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Feasibility of obtaining serial BIA-derived fluid markers during the initial HSCT hospitalization
Timeframe: Baseline (before transplantation), Day 0 (on day of transplant), Day 1-14 (every other day for initial two weeks post-transplant), Once a week during the initial hospitalization post-transplantation up to one year
Longitudinal changes in total body water (TBW)
Timeframe: Baseline (before transplantation), Day 0 (on day of transplant), Day 1-14 (every other day for initial two weeks post-transplant), Once a week during the initial hospitalization post-transplantation up to one year
Longitudinal changes in extracellular water (ECW)
Timeframe: Baseline (before transplantation), Day 0 (on day of transplant), Day 1-14 (every other day for initial two weeks post-transplant), Once a week during the initial hospitalization post-transplantation up to one year
Longitudinal changes in intracellular water (ICW)
Timeframe: Baseline (before transplantation), Day 0 (on day of transplant), Day 1-14 (every other day for initial two weeks post-transplant), Once a week during the initial hospitalization post-transplantation up to one year
Secondary (2)
Concordance between BIA-derived fluid markers and routine clinical fluid status assessments obtained at the same time points-Daily weight
Concordance between BIA-derived fluid markers and routine clinical fluid status assessments obtained at the same time points-Intake/Output
Arms and interventions
Hematopoietic stem cell transplantation (HSCT) recipients
Participants ages 6-21 years planned to undergo allogeneic or autologous HSCT for any indication with any preparative regimen who meet the eligibility criteria and consent will be enrolled. Routine bioimpedance device measurements will be taken at specific times during the participant's initial hospitalization after the transplant.
Diagnostic tests: Bioimpedance device
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States